Together, these results confirm that ERα can be expressed in human prostate tumors and suggest that ERα-positive or ERα-negative status may apply to PCa tumors and be pertinent for prognosis and repurposing of anti-estrogen therapies. The gene discussed is ESR1; the disease is posterior cortical atrophy.